A scientific study published in the journal Nature has revealed a significant breakthrough in the design of antibodies using artificial intelligence, which could revolutionize the pharmaceutical industry.

A team of scientists led by Nobel laureate Professor David Baker has successfully created new, fully effective antibodies through a generative AI model, a move that will significantly accelerate drug development.The new approach is based on the use of an artificial intelligence model dubbed RFantibody, an improved version of a model the team had previously developed to design proteins.